Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. More Details
High growth potential with imperfect balance sheet.
Share Price & News
How has Theranexus Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALTHX is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ALTHX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
7 Day Return
1 Year Return
Return vs Industry: ALTHX exceeded the French Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: ALTHX exceeded the French Market which returned 48.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Theranexus Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StTheranexus Société Anonyme's (EPA:ALTHX) Has Found A Path To Profitability
6 months ago | Simply Wall StIs Theranexus Société Anonyme (EPA:ALTHX) Weighed On By Its Debt Load?
7 months ago | Simply Wall StWe Might See A Profit From Theranexus Société Anonyme (EPA:ALTHX) Soon
Is Theranexus Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALTHX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALTHX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALTHX is unprofitable, so we can't compare its PE Ratio to the French Pharmaceuticals industry average.
PE vs Market: ALTHX is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALTHX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALTHX is overvalued based on its PB Ratio (5.9x) compared to the FR Pharmaceuticals industry average (3.3x).
How is Theranexus Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALTHX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: ALTHX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALTHX's is expected to become profitable in the next 3 years.
Revenue vs Market: ALTHX's revenue (24.9% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: ALTHX's revenue (24.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALTHX is forecast to be unprofitable in 3 years.
How has Theranexus Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALTHX is currently unprofitable.
Growing Profit Margin: ALTHX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALTHX is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.
Accelerating Growth: Unable to compare ALTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALTHX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.9%).
Return on Equity
High ROE: ALTHX has a negative Return on Equity (-60.61%), as it is currently unprofitable.
How is Theranexus Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: ALTHX's short term assets (€12.3M) exceed its short term liabilities (€3.9M).
Long Term Liabilities: ALTHX's short term assets (€12.3M) exceed its long term liabilities (€3.5M).
Debt to Equity History and Analysis
Debt Level: ALTHX's debt to equity ratio (52.9%) is considered high.
Reducing Debt: Insufficient data to determine if ALTHX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALTHX has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALTHX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Theranexus Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALTHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALTHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALTHX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALTHX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALTHX's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Franck Mouthon serves as the Chairman and Chief Executive Officer of Theranexus société anonyme and has been its Director since September 26, 2017. Mr. Mouthon is also an Administrator of France Biotec...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Franck's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: Franck's compensation has increased whilst the company is unprofitable.
Experienced Management: ALTHX's management team is considered experienced (4.3 years average tenure).
Experienced Board: ALTHX's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Theranexus Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Theranexus Société Anonyme
- Ticker: ALTHX
- Exchange: ENXTPA
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €47.987m
- Shares outstanding: 3.70m
- Website: https://www.theranexus.com
Number of Employees
- Theranexus Société Anonyme
- 60 avenue Rockefeller
- Pépinière Laennec
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company’s lead drug candidate is THN102, which is in Phase II cl...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 19:38|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.